Skip to main content
main-content

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

First-line avelumab investigated in cisplatin-unfit advanced UC patients

share
SHARE

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin (4:19).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.